3SBio Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, May 2011, Pages: 36

3SBio Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “3SBio Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- 3SBio Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of 3SBio Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of 3SBio Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the 3SBio Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate 3SBio Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of 3SBio Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the 3SBio Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with 3SBio Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of 3SBio Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
3SBio Inc. Snapshot
3SBio Inc. Overview
Key Information
Key Facts
3SBio Inc. – Research and Development Overview
Key Therapeutic Areas
3SBio Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
3SBio Inc. – Pipeline Products Glance
3SBio Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
3SBio Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
3SBio Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
3SBio Inc. – Drug Profiles
Feraheme
Product Description
Mechanism of Action
R&D Progress
NuLeusin
Product Description
Mechanism of Action
R&D Progress
Pegsitacase
Product Description
Mechanism of Action
R&D Progress
NuPIAO
Product Description
Mechanism of Action
R&D Progress
SSS07
Product Description
Mechanism of Action
R&D Progress
SSS08 Vaccine
Product Description
Mechanism of Action
R&D Progress
3SBio Inc. – Pipeline Analysis
3SBio Inc. – Pipeline Products by Therapeutic Class
3SBio Inc. - Pipeline Products By Target
3SBio Inc. – Pipeline Products by Route of Administration
3SBio Inc. – Pipeline Products by Molecule Type
3SBio Inc. – Recent Pipeline Updates
3SBio Inc. – Company Statement
3SBio Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
3SBio Inc., Deals Summary, 2004 to 2011
3SBio Inc. Detailed Deal Summary
Equity Offering
3SBio Completes Initial Public Offering Of $119.05 Million
Licensing Agreements
3SBio Enters Into Licensing Agreement With Panacor Bioscience
3SBio Enters Into Licensing Agreement With AMAG Pharmaceuticals For Ferumoxytol
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
3SBio Inc. – Pipeline by Therapy Area and Indication, 2011
3SBio Inc. – Pipeline by Stage of Development, 2011
3SBio Inc. – Monotherapy Products in Pipeline, 2011
3SBio Inc. – Filed, 2011
3SBio Inc. - Phase I, 2011
3SBio Inc. - Pipeline By Therapeutic Class, 2011
3SBio Inc. - Pipeline By Target, 2011
3SBio Inc. – Pipeline By Route of Administration, 2011
3SBio Inc. – Pipeline By Molecule Type, 2011
3SBio Inc. – Recent Pipeline Updates, 2011
3SBio Inc., Subsidiaries
3SBio Inc., Deals Summary, 2004 to 2011

List of Figures
3SBio Inc. – Pipeline by Therapy Area and Indication, 2011
3SBio Inc. – Pipeline by Stage of Development, 2011
3SBio Inc. – Monotherapy Products in Pipeline, 2011
3SBio Inc. – Pipeline By Therapeutic Class, 2011
3SBio Inc. - Pipeline By Target, 2011
3SBio Inc. – Pipeline By Route of Administration, 2011
3SBio Inc. – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• eBay - Strong Execution
• Accenture - Profile - US
• Dell - Profile - US